Characterization of Artificial Pneumothorax-Unrelated Pyothorax-Associated Lymphoma
Source : https://www.hindawi.com/journals/jo/2021/3869438/
Pyothorax-associated lymphoma (PAL) is a rare disease developing from a long-term pleural cavity inflammation. Most reported PAL cases have a history of artificial pneumothorax. However, the clinical features of artificial...
-
Mark Fesler4yrThis was an interesting read as I’ve never seen this subtype of lymphoma and is another example of how chronic inflammation can be a nidus for the development of lymphoma
-
Mark Fesler4yrThis is a challenging topic as we have very little data. Guidelines as this still play a role in getting individuals and institutions on the same page by providing a Show More
L-MIND Trial Results Show CD19 Antibody Is Reasonable in R/R DLBCL
Source : https://www.targetedonc.com/view/l-mind-trial-results-show-cd19-antibody-is-reasonable-in-r-r-dlbcl
During a Targeted Oncology Case Based Peer Perspectives Roundtable event, Loretta J. Nastoupil, MD, associate professor, director, Lymphoma Outcomes Database, section chief, New Drug Development, in the Department of Lymphoma/Myeloma,...
-
Mark Fesler4yrWe know from prior studies that lenalidomide carries a reasonable signal of efficacy, both in terms of response rate and prolonged response duration, in DLBCL. The L mind trial, Show More
Metabolomic approach to characterize the metabolic phenotypes and varied response to ouabain of diffuse large B-cell lymphoma cells
Source : https://doi.org/10.1080/10428194.2021.1881513
Abstract Abstract Germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtype diffuse large B-cell lymphoma (DLBCL) showed differential prognosis. Our results suggested that ouabain induced stronger inhibition of growth in...
-
Mark Fesler4yrMost novel therapies affect abc preferentially to the gcb subtype of DLBCL. This line of research holds some promise of understanding how we might further influence the gcb subtype Show More
CAR-T Therapy, the End of A Chapter or the Beginning of A New One?
Source : https://www.mdpi.com/2072-6694/13/4/853
Chimeric antigen receptor-T (CAR-T) therapy targeting CD19 has revolutionised the treatment of advanced acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL). The ability to specifically target the cancer...
-
Mark Fesler4yrAn overview of CART with projection about future potential and possiblities....